日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer.

PARP抑制剂在具有同源重组能力的去势抵抗性前列腺癌中引发不同的转录程序。

Cunningham Moriah L, Vasquez-Gonzalez Jasibel, Barnada Samantha M, Tchotorlishvili Salome, Jones Latese, Maguire Ryan, Lewis Genevieve, Rizwan Kinza, Deng Jenny, Koachar Salma, Patel Drithi, Shankle Hailey, Mulders Tessa, Ajmal Namra, Solomides Charalambos, Alnemri Emad S, Alnemri Teresa F, Shafi Ayesha A, Gomella Leonard G, Kelly Wm Kevin, McMahon Steven B, Schiewer Matthew J

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

对接受多西他赛/泼尼松联合或不联合贝伐珠单抗治疗的转移性去势抵抗性前列腺癌男性患者循环血浆生物标志物的预后和预测分析

Nixon, Andrew B; Liu, Yingmiao; Yang, Qian; Luo, Bin; Starr, Mark D; Brady, John C; Kelly, Wm Kevin; Beltran, Himisha; Morris, Michael J; George, Daniel J; Armstrong, Andrew J; Halabi, Susan

The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials

醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者的安全性:基于14项随机临床试验的个体参与者数据荟萃分析

Shaver, Amy L; Nikita, Nikita; Sharma, Swapnil; Keith, Scott W; Zarrabi, Kevin K; Kelly, Wm Kevin; Lu-Yao, Grace

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

T细胞重定向双特异性抗体:晚期前列腺癌免疫肿瘤学新方向综述

Palecki, Julia; Bhasin, Amman; Bernstein, Andrew; Mille, Patrick J; Tester, William J; Kelly, Wm Kevin; Zarrabi, Kevin K

The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study

接受阿比特龙或恩扎卢胺治疗的老年前列腺癌患者败血症发生率:一项基于人群的研究

Nikita, Nikita; Gandhi, Krupa; Keith, Scott W; Sharma, Swapnil; Kelly, Wm Kevin; Lu-Yao, Grace

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

尼拉帕尼联合镭-223治疗转移性去势抵抗性前列腺癌的I期研究

Quinn, Zachary; Leiby, Benjamin; Sonpavde, Guru; Choudhury, Atish D; Sweeney, Christopher; Einstein, David; Szmulewitz, Russell; Sartor, Oliver; Knudsen, Karen; Yang, Eddy Shih-Hsin; Kelly, Wm Kevin

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer

PARP 抑制和药理抗坏血酸在去势抵抗性前列腺癌中表现出协同作用

Nicolas Gordon, Peter T Gallagher, Neermala Poudel Neupane, Amy C Mandigo, Jennifer K McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J Paller, Wm Kevin Kelly, Karen E Knudsen, Ayesha A Shafi, Matthew J Schiewer

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence

治疗还是不治疗低危或中危前列腺癌患者——权衡证据

Halabi, Susan; Carthon, Bradley C; Kelly, Wm Kevin

Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis

黑人男性前列腺癌患者(符合美国国家综合癌症网络低风险前列腺癌标准)的格里森评分重新分类显著——倾向评分分析

Awasthi, Shivanshu; Mahal, Brandon A; Park, Jong Y; Creed, Jordan H; Williams, Vonetta L; Elkenawi, Asmaa; Meadows, Sylvester O; Pow-Sang, Julio M; Lu-Yao, Grace; Kelly, Wm Kevin; Lang, Damaris-Lois Y; Zgibor, Janice; Rebbeck, Timothy R; Yamoah, Kosj

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer

一项随机II期研究,比较雄激素剥夺疗法联合或不联合帕博西尼治疗RB阳性转移性激素敏感性前列腺癌的疗效

Palmbos, Phillip L; Daignault-Newton, Stephanie; Tomlins, Scott A; Agarwal, Neeraj; Twardowski, Przemyslaw; Morgans, Alicia K; Kelly, Wm Kevin; Arora, Vivek K; Antonarakis, Emmanuel S; Siddiqui, Javed; Jacobson, Jon A; Davenport, Matthew S; Robinson, Dan R; Chinnaiyan, Arul M; Knudsen, Karen E; Hussain, Maha